CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
A081801 Alliance Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO Adult CIRB - Late Phase Emphasis
A082002 Alliance A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or without SBRT for PD-L1-Negative, Advanced Non-small Cell Lung Cancer Adult CIRB - Late Phase Emphasis
A082101 Alliance Multimodality Therapy with Immunotherapy in Stage I-IIIA Sarcomatoid Mesothelioma Adult CIRB - Late Phase Emphasis
A091105 Alliance A Phase III; Double Blind; Randomized; Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF) Adult CIRB - Late Phase Emphasis
A091202 Alliance A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma
Agonist; Efatutazone in Patients with Previously Treated; Unresectable Myxoid Liposarcoma 		Adult CIRB - Early Phase Emphasis
A091304 Alliance A Phase I /Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib In Patients With Locally Advanced/Unresectable And/Or Metastatic Sarcoma Adult CIRB - Early Phase Emphasis
A091401 Alliance Randomized Phase II Study Of Nivolumab With Or Without Ipilimumab In Patients With Metastatic Or Unresectable Sarcoma Adult CIRB - Late Phase Emphasis
A091404 Alliance A Phase II Study of Enzalutamide (NSC# 766085) for Patients with Androgen Receptor Positive Salivary Cancers Adult CIRB - Late Phase Emphasis
A091603 Alliance A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Adult CIRB - Late Phase Emphasis
A091605 Alliance A Randomized Phase II Study of anti-PD1 antibody [MK-3475 (pembrolizumab)] alone versus anti- PD1 antibody plus Stereotactic Body Radiation therapy in advanced Merkel Cell Carcinoma Adult CIRB - Late Phase Emphasis